| Document |
Document Title |
|
WO/2008/119773A1 |
The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H,C 1-C 6 alkyl, C 3-C 6 cycloalkyl, aryl or heteroc...
|
|
WO/2008/119772A1 |
The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H, C1-C6alkyl, C3-C6cycloalkyl, aryl or heterocyclyl...
|
|
WO/2008/114022A1 |
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as "BPSAAA compounds"), as described herein, and in...
|
|
WO/2008/113756A2 |
The invention relates to aryl-sulphonamido compounds endowed with inhibitory activity against metallo proteases MMP, having Formula (I) below wherein R, R 1, R 2, R 3, R 4, R 5, n and m have the meanings reported in the specification; th...
|
|
WO/2008/113760A2 |
The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R denotes a group of formula (A) wherein X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof ...
|
|
WO/2008/114831A1 |
Disclosed is an antibacterial agent or the like, which contains a compound having excellent antibacterial activity against drug-resistant bacteria such as MRSA and VRE. The compound has a simple structure and can be easily produced comme...
|
|
WO/2008/109991A1 |
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...
|
|
WO/2008/110698A2 |
The invention relates to a method for preparing polyfluorinated sulphanylamides of formula (I) and polyfluorinated sulphinamidines of formula (II), wherein R1-R4 are defined as in the claims, and for preparing the precursors of same.
|
|
WO/2008/107661A1 |
There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which...
|
|
WO/2008/107176A1 |
The invention relates to meta-substituted phenyl sulfonyl amides of secondary amino acid amides according to the general formula (I), (II), or (III), the production thereof, and the use thereof as matriptase inhibitors, in particular the...
|
|
WO/2008/105386A1 |
Disclosed is a compound represented by the general formula shown below, which can bind to a retinoid X receptor (RXR) (which is one of nuclear receptors) to exhibit an agonistic or antagonistic activity on the receptor. wherein R1 is sel...
|
|
WO/2008/101810A1 |
The present invention relates to washing and cleaning compositions comprising urea derivatives and to the use of these washing and cleaning compositions for cleaning of textiles and surfaces.
|
|
WO/2008/102908A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/099727A1 |
Disclosed is a novel α-substituted acrylate derivative which is useful as a material for a polymer compound for photoresist compositions which is excellent in control of dissolution rate, while maintaining high transparency around 193 n...
|
|
WO/2008/098244A1 |
The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides f...
|
|
WO/2008/093767A1 |
Disclosed are: a benzylamine derivative typified by the formula below and a pharmaceutically acceptable acid addition salt thereof; a pharmaceutical agent comprising the derivative or the pharmaceutically acceptable acid addition salt th...
|
|
WO/2008/088727A2 |
This invention relates to novel endothelin receptor antagonists of the formula (I), derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of...
|
|
WO/2008/083729A1 |
The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging.
|
|
WO/2008/077070A2 |
Described herein are methods for rational design of inhibitors of HIV-1 protease, and crystal structures of HIV-1 protease inhibitors bound to HIV-1 protease.
|
|
WO/2008/074132A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
WO/2008/074755A2 |
This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are respons...
|
|
WO/2008/075353A1 |
The present invention relates to sulfonamide derivatives of formula (I) (wherein R1, R2, R3, R3', R4and R5are as defined in the claims), to pharmaceutical compositions comprising the same, and to uses thereof. Compounds of the invention ...
|
|
WO/2008/071398A1 |
The present invention relates to the use of a sulfonamide compound of formula (I): wherein R1 is selected from the group consisting of H, CN, halogen, trifluoromethyl, methyl, ethyl, hydroxy, methoxy, ethoxy, morpholino, R2 is selected f...
|
|
WO/2008/073789A1 |
The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
|
|
WO/2008/071421A1 |
Nitroderivatives of carbonic anhydrase inhibitors having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration...
|
|
WO/2008/068170A1 |
The use of compounds of the formula (I): Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2 where Y is selected from O or S; R1 is H, a salt or readily hydrolysable substituent; R2 is selected from H or CH3, CH2F, CF2H or CF3; R3 and R4 are selected ...
|
|
WO/2008/064595A1 |
5-[(2R)-[2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]
propyl]-2-methoxybenzenesulfonamide, a pharmaceutical composition containing the compound, and the synthesis method thereof. The compound has strong antagonism toward α1-adren...
|
|
WO/2008/059335A1 |
Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described her...
|
|
WO/2008/061006A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof, which are modulators of secreted frizzled related protein- 1, are disclosed. The compounds, and compositions containing the compounds, can be used to treat various d...
|
|
WO/2008/059800A1 |
The invention aims at providing compounds which have sufficiently high affinity for NMDA receptor and can inhibit the inflow of calcium ions efficiently and which have low cytotoxicity and low molecular weights and can be expected to exh...
|
|
WO/2008/050125A1 |
There is provided a compound of formula (I) wherein R1a, R2a, R3, X1 to X6, a, b and c have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, inhibitors of HDAC enzyme activity, and thus, in ...
|
|
WO/2008/050168A1 |
The present invention relates to new sulfonamide derivatives of formula (I), wherein R1 -R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective ...
|
|
WO/2008/050167A1 |
The present invention relates to new sulfonamide derivatives of formula (I), wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective a...
|
|
WO/2008/045671A1 |
The present invention relates to compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are defined in the spoecification. In addition, the present invention relates to methods treating disorders related to matrix metalloproteas...
|
|
WO/2008/040947A2 |
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...
|
|
WO/2008/040934A1 |
Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or m...
|
|
WO/2008/037628A1 |
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein L, R1, R2, m and n have the meaning given in claim 1 and which can be used in the form of pharmaceutical compositions.
|
|
WO/2008/038640A1 |
Disclosed is a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. Also disclosed is a method for producing a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid.
|
|
WO/2008/040000A2 |
Disclosed are sulfonamide compounds of formula (I), wherein R1-R3, Y and m are as defined in the claims, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for...
|
|
WO/2008/035677A1 |
Disclosed are novel chlorofluorosulfonimides and methods for producing such chlorofluorosulfonimides. Specifically disclosed are a compound (1) represented by the following formula: [M]n+([RF-SO2-N-SO2-QF-Cl]-)n; a compound (2) represent...
|
|
WO/2008/029810A1 |
Disclosed is a pest control agent having a high, stable pest control effect. Specifically disclosed is a phenylguanidine derivative represented by the formula (I) below or a salt thereof. (In the formula, R1 represents a hydrogen, an alk...
|
|
WO/2008/028937A1 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: Formula (I) wherein the groups R1-R5, R10 and X1-X7 are as defined in the specification.
|
|
WO/2008/027604A2 |
RF-compositions including surfactants, foam stabilizers, monomers, polymers, urethanes, intermediates, metal complexes, phosphate esters as well as telomerization methods are provided.
|
|
WO/2008/026563A1 |
A novel compound having an NPY Y5 receptor antagonism is provided. The compound is a compound represented by the formula: (wherein R1 represents lower alkyl which may have a substituent, etc., R2 and R8 independently represent hydrogen o...
|
|
WO/2008/024746A1 |
Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
|
|
WO/2008/024303A2 |
Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variabables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a prolifer...
|
|
WO/2008/021804A2 |
Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.
|
|
WO/2008/017840A1 |
The invention relates to cyclopentanecarboxylic acid derivatives and related compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 are as described in the specification, processes for the preparation thereof, pharmaceutical composi...
|
|
WO/2008/018544A1 |
Disclosed is a sulfonamide compound having a chemical structure characterized in that the compound has an amide structure wherein a carbon atom in the amide binds to a nitrogen atom in a sulfonamide through a lower alkylene, or a salt of...
|
|
WO/2008/017925A2 |
Compound featuring a hypoglycemic action and in the meantime a release of nitric oxide (NO), said compound having the following general formula (I) : where at least one among R, R1, and R2 is a substitute comprising an nitroxy-ester grou...
|
